Institutional members access full text with Ovid®

Share this article on:

Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience

Sio, Terence T. MD, MS; Wilson, Zachary C. MD; Stauder, Michael C. MD; Bhatia, Sumita MD; Martenson, James A. MD; Quevedo, J. Fernando MD; Schomas, David A. MD; Miller, Robert C. MD, MS

American Journal of Clinical Oncology: October 2016 - Volume 39 - Issue 5 - p 448–452
doi: 10.1097/COC.0000000000000089
Original Articles: Thoracic

Objectives: To determine long-term outcomes in patients with locally advanced esophageal carcinoma treated with trimodality therapy (chemoradiotherapy [CRT] and surgery, TMT) or definitive CRT.

Methods: We retrospectively identified patients with advanced esophageal carcinoma treated with curative intent at our institution between 1998 and 2004. Identified patients were separated into 3 groups: patients who received TMT, patients who received CRT, and patients who began treatment with trimodality intent but did not undergo surgery (PTMT). Local control, overall survival (OS), and distant metastasis-free survival were compared using Kaplan-Meier statistics.

Results: Among the 265 patients included, median follow-up was 6.4 years for surviving patients and 1.7 years for all patients. Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%). Treatment groups comprised 169 patients (64%) completing TMT, 46 patients medically unable to undergo surgery after neoadjuvant therapy (PTMT), and 50 (19%) who underwent CRT. Median OS was 20.5 months; actuarial 5- and 10-year OS were 27% and 12%, respectively. The TMT group had the highest 5- and 10-year OS (32% and 19%, respectively). Local control rates at 2, 5, and 10 years for all patients were 80%, 70%, and 69%, respectively. By treatment modality, 5-year local control was best (82%) for TMT, compared with 60% for CRT and 40% for PTMT groups (P<0.001).

Conclusions: Patients who completed TMT had the best local control and long-term OS. In the context of TMT, surgery seemed more beneficial in patients with esophageal adenocarcinoma versus squamous cell carcinoma.

*Department of Radiation Oncology

Division of Medical Oncology, Mayo Clinic, Rochester, MN

West Hills Radiation Therapy Center, West Hills, CA

§Radiation Oncology Department, Therapeutic Radiologists Inc., Kansas City, MO

T.T.S. and Z.C.W. are the co-first authors and contributed equally.

The authors declare no conflicts of interest.

Reprints: Robert C. Miller, MD, MS, Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.